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In Brief
Smyllie et al. use a fluorescent reporter
mouse to image the circadian dynamics
of PER2, a key component of the
circadian clock in the suprachiasmatic
nucleus and fibroblasts. They reveal
marked divergence of the mechanisms of
mouse and fly clock cells, and they
provide quantitative data to support
reappraisal of current models of the
mammalian clock.
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SUMMARY
Transcriptional-translational feedback loops (TTFLs)
are a conserved molecular motif of circadian clocks.
The principal clock in mammals is the suprachias-
matic nucleus (SCN) of the hypothalamus. In SCN
neurons, auto-regulatory feedback on core clock
genes Period (Per) andCryptochrome (Cry) following
nuclear entry of their protein products is the basis of
circadian oscillation [1, 2]. In Drosophila clock neu-
rons, the movement of dPer into the nucleus is sub-
ject to a circadian gate that generates a delay in the
TTFL, and this delay is thought to be critical for oscil-
lation [3, 4]. Analysis of the Drosophila clock has
strongly influenced models of the mammalian clock,
and such models typically infer complex spatiotem-
poral, intracellular behaviors of mammalian clock
proteins. There are, however, no direct measures of
the intracellular behavior of endogenous circadian
proteins to support this: dynamic analyses have
been limited and often have no circadian dimension
[5–7]. We therefore generated a knockin mouse ex-
pressing a fluorescent fusion of native PER2 protein
(PER2::VENUS) for live imaging. PER2::VENUS reca-
pitulates the circadian functions of wild-type PER2
and, importantly, the behavior of PER2::VENUS runs
counter to the Drosophila model: it does not exhibit
circadian gating of nuclear entry. Using fluorescent
imaging of PER2::VENUS, we acquired the first
measures of mobility, molecular concentration, and
localization of an endogenous circadian protein in in-
dividual mammalian cells, and we showed how the
mobility and nuclear translocation of PER2 are regu-
lated by casein kinase. These results provide new
qualitative and quantitative insights into the cellular
mechanism of the mammalian circadian clock.
RESULTS
Generation and Validation of PERIOD2::VENUS Mouse
We used homologous recombination to knock in a fluorescent
tag at the Per2 locus, an equivalent strategy to that used for
the PER2::LUC mouse, which is known to exhibit wild-type
(WT) PER2 behavior [8]. Venus was fused to exons 19–23 of
mPer2 (Figure S1A). The presence of PER2::VENUS protein
expression was confirmed by fluorescence microscopy in
the brain and in lung fibroblasts (Figures 1A and 1B). As
well as strong fluorescence in the suprachiasmatic nucleus
(SCN), limited expression was observed in the piriform cortex,
thalamus, and hippocampus (Figure S1B). Importantly, the
spatial distribution of PER2::VENUS co-localized completely
with PER2 immunoreactivity (-ir) in Per2WT/Venus SCN (Figures
S1C–S1E).
To test for normal circadian function in Per2Venus/Venus animals,
we first assessed wheel-running behavior. They entrained effec-
tively to a 12-hr light/12-hr dark schedule (12:12 LD), and they
exhibited consolidated circadian activity patterns of wheel-
running when placed in constant conditions (Figures 1C, S1F,
and S1G). There were no significant differences between WT
and Per2Venus mice in the distribution, structure, or robustness
(measured by non-parametric circadian rhythm analysis) of
circadian behavior. After crossing with Per1-luc reporter mice,
Per2Venus/Venus SCN organotypic slices expressed robust, high-
amplitude circadian bioluminescence rhythms (Figures 1D and
S1H). The circadian periods of behavioral and SCN rhythms
were not significantly different between WT and Per2Venus/Venus
mice (Figures 1E and 1F). Thus, PER2::VENUS did not compro-
mise molecular pacemaking in the SCN or effective circadian
control over behavior. To confirm that Per2Venus did not encode
a loss-of-function mutation, Per2Venus mice were crossed to
Per1/ mice. In the absence of PER1, WT PER2 is a necessary
and sufficient component of the circadian pacemaker [9].
Per2Venus/Venus, Per1/ mice exhibited robust and sustained
wheel-running and SCN bioluminescence rhythms (Figures S1I
and S1J), with comparable periods to Per2WT/WT, Per1/ mice
(Figure S1K). Thus, Per2Venus encodes a functional allele of
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PER2. Per2Venus mice were then crossed with CK1εTau mutants
to test whether PER2::VENUS can interact with CK1ε, a key
modulator of PER2 stability and circadian period [10]. In WT an-
imals, the CK1εTau/Tau mutation shortened period from 24 to
20 hr (Figures S1I, S1J, and S1L) [10]. Per2Venus/Venus mice
showed comparable acceleration of SCN and behavioral
rhythms. Thus, Per2Venus encodes an endogenous fusion protein
that functions competently within the mammalian clock.
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Figure 1. PER2::VENUS Fusion Protein Is a Competent Circadian Clock Protein Suitable for Real-Time Imaging
(A) PER2::VENUS fluorescence across the mouse brain, at the peak time of SCN expression (ZT12). Inset shows a close up of the SCN. Scale bar, 1 mm.
(B) Bright-field and fluorescence confocal images show Per2Venus lung fibroblasts. Scale bar, 20 mm.
(C) Representative, double-plotted wheel-running actograms for Per2WT (left) and Per2Venus (right) animals. Mice were entrained on a 12:12 LD cycle, followed by
a schedule of constant conditions (dim red light, represented by shaded gray).
(D) Representative, de-trended Per1-luc bioluminescence rhythms of SCN slices from Per2WT (left) and Per2Venus (right) mice are shown.
(E) Mean ± SEM circadian periods for wheel-running are shown (nWT = 6; nWT/V = 8; nV/V = 7).
(F) Mean ± SEM circadian periods for SCN slices (nWT = 6; nWT/V = 7; nV/V = 9). One-way ANOVA revealed no significant effect for either measure.
(G) Snapshots from confocal real-time imaging show PER2::VENUS fluorescence in representative Per2Venus (top panel), Per1 null (middle panel), and CK1εTau
(lower panel) in SCN slices.
(H) Snapshots from confocal real-time imaging show PER2::VENUS in fibroblasts. Scale bar, 20 mm.
(I) Mean fluorescence measures from recordings in (G) are shown.
(J) Mean fluorescence measures from recordings in (H) are shown.
See also Figure S1, Table S1, and Movie S1.
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Intracellular Circadian Dynamics of Endogenous
PERIOD2
We next analyzed the rhythmicity of the PER2::VENUS protein.
A clear circadian oscillation of PER2::VENUS abundance was
detected by western blot in temperature-entrained lung fibro-
blasts (Figures S1M and S1N). PER2::VENUS was also highly
and rhythmically expressed in the SCN (Figures S1O and S1P).
At the peak of PER2 expression (zeitgeber time 12 [ZT12]), in
the SCN, PER2::VENUS was detected in effectively all arginine
vasopressin (AVP)-immunoreactive (ir) and vasoactive intestinal
peptide (VIP)-ir neurons but in <10% of gastrin-releasing peptide
(GRP)-ir neurons (Figure S2; Table S1). At the trough of the cycle
(CT0), only a few AVP-ir cells expressed PER2::VENUS (Table
S1). We next tested the utility of PER2::VENUS as a real-time
circadian reporter, using confocal microscopy. Both SCN slices
and lung fibroblasts exhibited stable, high-amplitude circadian
oscillations of fluorescence throughout 70 hr of recording (Fig-
ures 1G and 1H; Movie S1). In the SCN, PER2::VENUS peaked
appropriately at 1 and 4 hr, respectively, after Cry1-luc and
Per1-luc (Figures S3A and S3B). Circadian expression of PER2::
VENUS was well defined in the SCN with a Per1/ background
and accurately reported period shortening by the CK1εTaumuta-
tion. Thus, PER2::VENUS is a high-fidelity real-time reporter of
the behavior of an endogenous clock protein in SCN neurons
and fibroblasts.
We next determined the macrodynamics of PER2::VENUS.
Using cycloheximide to inhibit translation in SCN slices, we re-
vealed that PER2::VENUS has a half-life of2 hr, comparable
to that of PER2::LUC (Figures S3C–S3E) [10]. Consistent with
proteasomal degradation of Per2WT [11], application of the pro-
teasomal inhibitor MG132 at CT12 increased PER2::VENUS
levels above thoseof vehicle-treated lung fibroblasts (FigureS3F)
and SCN slices (Figures S3G and S3H). The nuclear export inhib-
itor leptomycin B, applied at CT12, significantly increased the
half-life of PER2::VENUS, suggesting that nuclear export facili-
tates degradation (i.e., PER2 is subject to degradation in the
cytoplasm; Figures S3I and S3J). Moreover, synchronization be-
tween cells in SCN slices was reduced following nuclear export
blockade, suggesting that timely nuclear export and degradation
are necessary for transcriptional-translational feedback loop
(TTFL) timing.
Gated nuclear entry of Per protein is considered a pivotal
feature of circadian timekeeping. We examined the subcellular
localization of PER2::VENUS in the SCN at different points
across the LD cycle. Although the overall abundance of
PER2::VENUS changed across the cycle, its subcellular localiza-
tion did not (Figure 2A). Mander’s M1 coefficient indicated
almost complete co-localization of Venus with nuclear DAPI
signal at all phases (Figure 2B): at no point was PER2::VENUS
excluded from the nucleus, with exclusively cytoplasmic
localization. To discount the possibility of a transient gate for
cytoplasmic retention and nuclear entry, cellular localization
was monitored in living SCN slices imaged during the rising
phase (CT0–CT9) of PER2 expression. Again, when detected,
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Figure 2. Circadian Subcellular Localization of PER2::VENUS
(A) Representative confocal images of SCN neurons from brain sections taken from Per2Venus animals across the LD cycle. PER2::VENUS -positive (green)
localization was compared with cytoplasmic immunostaining for AVP (red) and nuclear staining of DAPI (blue). Scale bar, 20 mm.
(B) Co-localization of PER2::VENUS and DAPI assessed by Mander’s coefficient analysis (M1, blue, co-localization of PER2::VENUS with DAPI; M2, yellow, co-
localization of DAPI with PER2::VENUS). Note that M2 changes across the day because the overall level of PER2::VENUS changes; thus, the proportion of DAPI
nuclei containing PER2::VENUS changes.
(C) Per2Venus SCN slices were fixed, counterstained with DAPI (blue), and imaged at different time points during the rising phase (CT0–CT9) of the PER2 circadian
cycle. Each image shows representative neurons found at that time point, rather than a representative field of view at that time point.
See also Figure S2.
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PER2::VENUS was observed in the nucleus at all time points
(Figure 2C). This was also the case in fibroblasts, where (weak)
cytoplasmic fluorescence oscillated in phase with strong
nuclear fluorescence (Figures S3K–S3M). Thus, in marked
contrast to the temporal gating that delays Drosophila Per entry
to the nucleus to late subjective day (4, 5), the mouse ortholog,
PER2, is not subject to compartmental circadian gating in
SCN neurons or fibroblasts and nuclear accumulation occurs
progressively.
Quantitative Analysis of PERIOD2 Intracellular Mobility
and Abundance
Fluorescence correlation spectroscopy (FCS) was used to mea-
sure mobility and molecular abundance of PER2::VENUS in skin
fibroblasts (Figure 3A). Circadian changes in PER2::VENUS con-
centration were observed in fibroblast nuclei (Figure 3B); but,
importantly, calibration of fluorescence intensity to FCS-calcu-
lated concentration per nuclear volume enabled absolute quan-
tification of the molecular abundance of PER2::VENUS across
the circadian cycle (Figures 3C and S4A–S4D). This revealed a
10-fold amplitude cycle, with peak expression of 15,000
molecules per nucleus (>90% of cellular total; Figure 3D). Inter-
estingly, when FCS-derived auto-correlations were fit to a two-
component diffusion model, a bimodal distribution of diffusion
coefficients was determined for nuclear PER2. This indicates
that it exists in at least two molecular/dynamic states, possibly
as bound and unbound fractions (Figure 3E). The more mobile
fraction had a diffusion coefficient of 8 mm2s1. Furthermore,
at CT12 the number of nuclear PER2::VENUS molecules, their
diffusion rates, and the proportion displaying the slowly diffusing
component were not significantly different in CK1εTau fibroblasts
compared to WT (Figures S3E–S3G). This suggests that PER2
mobility within the nucleus is not affected in the mutant. Thus,
we have presented the first quantitative measures of intracellular
dynamics of a mammalian circadian clock protein.
Fluorescence recovery after photobleaching (FRAP) was used
to further examine the intracellular behavior of PER2::VENUS.
Data obtained by photobleaching of fibroblast nuclei agreed
with the FCS-based calculations that intranuclear PER2 mobility
was unaffected by the CK1εTau mutation (Figure S4H). Further-
more, after bleaching nuclear fluorescence, full recovery of nu-
clear fluorescence did not occur within the experimental time
frame, confirming that the bulk (>90%) of PER2::VENUS was nu-
clear (Figure S4I). FRAP also was measured in SCN slices (Fig-
ure 4), yielding diffusion coefficients within cytoplasm or nucleus
of0.2 mm2s1. This is comparable to the slow diffusing compo-
nent revealed by FCS in fibroblasts (Figure 3E). The diffusion co-
efficient was calculated for both cytoplasm and nucleus, at CT12
and CT2. Intracompartment mobility was comparable for both
cytoplasm and nucleus at both time points (Figure 4D). PER2
mobility was not reduced in the nucleus, which may have been
expected for a transcriptional regulator. Translocation of PER2
into the nucleus is critical for the circadian TTFL [6, 7]. Thus,
T1/2 of FRAP was measured after photobleaching either the
whole nucleus or cytoplasm (Figures 4B and 4C; Movie S2) to
quantify between-compartment mobility. Importantly, this
showed that there is no compartmental or temporal restriction
over the mobility of PER2::VENUS (Figure 4E), in agreement
with the confocal time-lapse imaging data (i.e., movement be-
tween compartments was comparable in both directions).
CK1d/ε activity is an important regulator of the TTFL, where
CK1-mediated phosphorylation of PER proteins licenses them
for ubiquitination and proteasomal degradation. To test whether
CK1 modulates PER2 mobility, we treated SCN slices with
CK1 inhibitor PF670462, which slowed Per1-luc oscillations
to 28.6 ± 0.30 hr (n = 10, p < 0.01 versus pre-treatment).
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Figure 3. FCS of PER2::VENUS Protein in
Fibroblasts
(A) Schematic diagram illustrating the FCS proce-
dure. PER2::VENUS fluorescence was monitored
within a small confocal volume. Individual fluores-
cent molecules passed through the volume at a
given rate. The fluorescence signal of all of the
molecules in the volume was followed through
time. The concentration and rate of movement of
molecules were calculated by auto-correlating the
fluorescence signal.
(B) Fluorescence images and FCS-calibrated
quantification of PER2::VENUS concentration in
skin fibroblasts are shown.
(C) Circadian variation of nuclear concentration of
PER2::VENUS over time for eight representative
cells. Images were collected every 6 min but every
tenth image was analyzed; thus, there is a data
point every 1.12 hr.
(D) PER2::VENUS concentration in the nucleus at
CT12 (4–6 hr after temperature synchronization) is
shown (mean ± SEM).
(E) FCS data fit to a two-component diffusion
model, color coded by component (fast, light blue;
slow, dark blue), are shown.
See also Figures S3 and S4.
Current Biology 26, 1880–1886, July 25, 2016 1883
Intracompartment mobility was unaffected by treatment with
PF670462 (Figures S4J and S4K); but, surprisingly, both at
CT2 and CT12 it significantly decreased the T1/2 of FRAP (Fig-
ure 4E; i.e., the rates of PER2::VENUS bi-directional transloca-
tion were accelerated). Furthermore, the magnitude of the in-
creases in T1/2 were consistent across time points (CT2/CT12)
and direction of movement (Figure S4K). Thus, decreasing CK1
activity increased PER2::VENUS translocation rates in an unbi-
ased manner. In conclusion, low CK1ε/d activity, which signifi-
cantly lengthened the period of the SCN TTFL, was associated
with accelerated nucleo-cytoplasmic shuttling of PER2::VENUS.
DISCUSSION
The PER2::VENUS mouse enables direct qualitative and quanti-
tative observations of the complex spatiotemporal behavior of
the PER2 protein, in a physiologically relevant setting. Our results
suggest a pivotal role for the dynamic balance of nuclear entry
and export for the determination of circadian period.
The PER2::VENUS allele was validated as clock competent, a
property shared with PER2::LUC [8, 12]. Luciferase reporter sys-
tems, however, are not suitable for measuring fast events, such
as nucleo-cytoplasmic shuttling of proteins. They produce a dim
signal necessitating a long integration time for detection, and
their inherent requirement for luciferin substrate can generate
luciferase-chemistry-dependent artifacts. Fluorescent proteins
do not suffer from these problems, but there are, of course,
some potential limitations, including altered stability of the
endogenous protein. The half-life of PER2::VENUS was similar
to PER2::LUC, suggesting that the Venus tag did not alter the
stability of the PER2 protein. PER2::LUC had a slightly shorter
half-life, but this is in line with published literature reporting
that luciferase-tagged reporters have a shorter half-life than their
endogenous counterparts [13]. The PER2::VENUS half-life may
be a more accurate estimate of PER2 stability, as it is a direct
measure of the protein, rather than using enzymatic luciferase
activity, which is an indirect measure. Prolonged fluorescence
imaging can cause both phototoxicity and photobleaching, but
for PER2::VENUS we found that it was possible to image SCN
slices and fibroblast cultures over at least 70 hr without loss
of fluorescence or circadian competence. Although there was
limited detection of cytoplasmic PER2::VENUS in fibroblasts,
photobleaching of the entire cytoplasm only reduced the nuclear
fluorescence by <2% at CT12; thus, it is unlikely to contribute
to the overall behavior of PER2 in this cell type. Overall, PER2::
VENUS is a useful and faithful reporter for monitoring PER2
dynamics over shorter and longer timescales.
In contrast to the Drosophila ortholog, dPer, which accumu-
lates in the cytoplasm prior to nuclear entry [3, 4], PER2 is not
subject to a circadian gate in SCN neurons and in fibroblasts.
This contrasting behavior may be explained by the proteins
having different hetero-dimerization partners (dTim and CRY,
respectively). Our data do not preclude nuclear gating of other
clock factors, but there is, so far, no evidence for this. For
example, snapshot immunostaining of PER1 in SCN highlights
nuclear expression and no cytoplasmic restriction [14]. Pro-
gression of the TTFL in the mammalian clock, therefore, is
not dependent on gated nuclear translocation; rather, it is
achieved by graded nuclear accumulation of the negative
regulators.
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Figure 4. FRAP Reveals Role of CK1 in
Regulating PER2 Mobility in SCN Neurons
(A) A schematic diagram illustrating FRAP as fol-
lows: (1) select region and measure pre-bleach
fluorescence, (2) photobleach region, and (3)
monitor the recovery of fluorescence. The T1/2 is
calculated from the recovery curve.
(B) Snapshots from a FRAP experiment show
cytoplasmic photobleaching and fluorescence re-
covery in neurons in an SCN slice.
(C) Fluorescence recovery for a bleached cyto-
plasmic region (red) and unbleached nuclear
region (blue). The latter shows no change in fluo-
rescence over the time course.
(D) FRAP-derived diffusion coefficients (mean ±
SEM) within SCN nucleus and cytoplasm were
comparable at both peak and trough (CT2
and CT12) of the cycle (nCT2,cyto = 3 slices,
nCT12,cyto = 4, nCT2,nuc = 3, and nCT12,nuc = 4; two-
way ANOVA). Diffusion coefficients were esti-
mated from FRAP-derived T1/2 measures.
(E) FRAP-derived T1/2 (mean ± SEM) calculated
from total cytoplasm (Nuc to Cyto) and total
nucleus (Cyto to Nuc) FRAP of SCN neurons at
CT2 (left) and CT12 (right). Treatment with
PF670462 (1 mM) significantly decreased T1/2
times for PER2::VENUS (nCT2,WT,cyto = 4 slices,
nCT2,WT,nuc = 4, nCT2,PF,cyto = 5, nCT2,PF,nuc = 5,
nCT12,WT,cyto = 5, nCT12,WT,nuc = 6, nCT12,PF,cyto = 13,
and nCT12,PF,nuc = 12; two-way ANOVA with
Tukey’s comparison, ****p < 0.0001).
See also Figure S4 and Movie S2.
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PER2::VENUS enabled us to quantify the number of PER2
molecules per cell and determine the dynamic changes in pro-
tein mobility. At CT12, PER2::VENUS was present at a concen-
tration of 15–20 nM in fibroblast nuclei, equating to >10,000
molecules. Interestingly, stochastic simulations of the mamma-
lian circadian clock predicted that stability within the virtual
TTFL required >4,000 molecules [15]. Thus, our real observa-
tions are of the same order of magnitude and can inform future
development of in silico models. The Per2Venusmouse also facil-
itates analysis of how the intracellular behavior of PER2 directs
the properties of the clock. Both FRAP and FCS revealed diffu-
sion coefficients principally in the range of 0.1 to 1.0 mm2s1.
This is broadly compatible with data from other dynamic
transcription factor proteins [16]. FCS also identified a more
mobile fraction in fibroblasts, with a coefficient of 10 mm2s1.
The obtained fast and slow diffusion constants (10 and
1 mm2s1), as well as free and bound fractions, are comparable
to estimates made by FCS for the in vivo binding of glucocorti-
coid receptor [17].
Numerous studies link CK1 to the regulation of PER2 function
and localization [18–20]. Both CK1εTau and hPer2S662G are mu-
tants that have a short circadian period, with altered phosphor-
ylation of PER2. The former exhibits rapid clearance of PER2
from the nucleus [10, 21] and the latter decreased nuclear reten-
tion [22–24]. These are two aspects of the same phenomenon.
Our data demonstrate that CK1 contributes to the translocation
of PER2 through the nuclear pores. Thus, CK1 is a critical regu-
lator of PER2 mobility and circadian period, although the contri-
bution of various types of mutation to short periods is not fully
resolved [25, 26].
In conclusion, PER2::VENUS operates as a functional circa-
dian protein, and it is sufficient to sustain timekeeping in the
absence of WT Per proteins. We believe that the fundamental
observations we have presented will support a significant reap-
praisal of themammalian clockmechanism and provide valuable
observational data on an endogenous clock protein that will
inform the development of enhanced quantitative models of
cellular circadian timekeeping.
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Fig. S1. Per2Venus  mice express a functional fusion protein that is sufficient to drive circadian 
rhythms in gene expression and behavior. Related to Figure 1. 
(A) A schematic diagram depicting the generation of the PER2::VENUS protein. The targetting 
construct contains exons 19-23 of Per2 followed by the sequence for Venus, with floxed 
neomycin as a selection marker. The targeting construct was inserted into the Per2 locus in the 
mouse by homologous recombination, where the 3’ end of the endogenous gene was replaced 
with the targeting construct. Neomycin was later removed using Cre-recombinase.  The final 
Per2Venus knock-in allele resulted in the expression of the PER2::VENUS (P2V) fusion protein. 
Locations of genotyping primers  are marked. P1+R1 gave a positive reaction in Per2WT animals, 
whereas P1 and R2 gave a positive reaction in Per2Venus animals. (B) Representative 
epifluorescence images showing PER2::VENUS expresson across the brain in both sagittal and 
coronal views. Snapshots of regions containing signficant PER2::VENUS expression are shown 
adjacent to the overview images. Their locations are marked with colored boxes. Fluorescence 
levels were particularly low in the piriform cortex and thalamus, so arrows highlighting cells have 
been included on the figure. (C) Representative confocal images showing the complete 
co-localisation of PER2::VENUS (green) with Per2-immunoreactivity (red) in SCN from  
Per2WT/Venus, thus animals expressing both native Per2WT and the Per2Venus alleles. Upper panel 
shows the entire SCN (scale bar =100 μm) and lower panel  shows close-up of individual cells 
(scale bar =20 μm). PER2::VENUS fluorescence intensity was highly correlated to Per2 
immunostaining. (D) A representative correlation plot of pixel intensity in the red (Per2-IR) and 
green (PER2::VENUS) channels. (E) Mander’s colocalization analysis indicated almost complete 
co-localization between the two channels (n =3). (F)  Normalized, mean ± SEM daily DD 
wheel-running activity profile of WT (nWT/WT =5) and Per2Venus/Venus (nV/V  =5) animals.   
(G) Non-parametric Circadian Rhythm Analysis (NPCRA) of 12 days of DD wheel-running data. 
Relative Amplitude (RA; left), Intradaily Variability (IV; centre) and Interdaily Stability (IS, right) 
were not significantly different between WT and Per2Venus (V) animals (nWT/WT =5;  nV/V =5; 
unpaired T-test), thus circadian robustness of wheel-running activity was not affected by the 
presence of the Per2Venus allele.  (H) Circadian parameters of ampitude (left) and Relative 
Amplitude Error (RAE) (right) of SCN slices were not significantly affected by the Per2Venus allele 
(nWT/WT =5; nWT/V =8; nV/V =9; one-way ANOVA). (I) Representative double-plotted actograms 
of wheel-running activity for Per1-/- (upper) and CK1εTau/Tau (lower) animals . Shaded areas mark 
times when lights are off. (J) Representative, de-trended Per1-luc bioluminescence rhythms from 
SCN slices. (K) In the absence of Per1 expression (Per1-/-; P1KO), SCN circadian period showed 
no significant effect of carrying the Per2Venus allele (Behavior: nWT,WT =5; nV,WT =7; nWT,P1KO  =3; 
nV,P1KO =7; SCN: nWT,WT =3; nV,WT =5; nWT,P1KO  =7; nV,P1KO =24; two-way ANOVA). (L) Both 
wheel-running behavior (left) and SCN slices (right) from Per2Venus/Venus animals reported the 
short-period mutant phenotype of the CK1εTau/Tau (Tau) allele (Behavior: nWT,WT =6; nV,WT =9; 
nWT,Tau  =5; nV,Tau =13; SCN: nWT,WT =7; nV,WT =6; nWT,Tau  =4; nV,Tau =4; two-way ANOVA with 
Tukey’s comparisons: **** p <0.0001). All bar charts show mean ± SEM of group data. (M) 
Western blot showing rhythms of PER2::VENUS abundance in temperature-entrained 
Per2Venus/Venus fibroblasts. (N) Band intensity measures for western blot shown in (M).   (O) 
Representative images of fluorescence in SCN sections across the day.   (P) Mean ± SEM counts 
of PER2::VENUS-positive cells from SCN sections taken from mice at different time points across 
the light-dark cycle.
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Fig. S2. Neurochemical identities of PER2::VENUS positive cells. Related to Figure 2.
Representative images of SCN brain sections, showing immunofluorescence of SCN 
neuropeptides (red) vasoactive intestinal peptide (VIP), arginine vasopressin (AVP) 
and gastrin releasing peptide (GRP), colocalized with PER2::VENUS fluorescence 
(green) and counterstained with DAPI (blue). (A) Low-power images showing the 
whole SCN sections taken at ZT0 (left) and ZT12 (right). Scale bar = 100 uM. (B) 
Images showing “close-up” view of neuropeptide colocalization in the SCN at ZT12. 
The boxes (white for merged, red for neuropeptide and bue for DAPI channels), draw 
attention to positive colocalization of PER2::VENUS with VIP and AVP, but absence 
with GRP. Scale bar = 50 uM.
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Fig. S3. Probing PER2::VENUS macrodynamics using reporters and pharmacological agents. Related 
to Figure 3.
 (A) Representative traces showing consecutive recording of Cry1-luc (left) or Per1-luc (right) 
reporter bioluminescence measured by PMT followed by PER2::VENUS fluorescence (blue) captured 
by confocal microscopy, within the same slice. Dotted lines represent extrapolated rhythms of the 
bioluminescence reporters. (B) Phase-mapping circadian reporters on to PER2::VENUS. Peak times 
(mean ± SEM) of reporter circadian rhythms relative to PER2::VENUS, quoted as time prior to 
PER2::VENUS peak. (C) 24 hour recordings of PER2::LUC bioluminescence and PER2::VENUS 
fluorescence in SCN slices (n = 3 per group) treated with cycloheximide (40 μM; red trace) or vehicle 
(grey) at the peak of Per2 expression.  (D) Using the data shown in (C), a one-phase exponential 
decay was fitted to the “peak-to-trough” of traces (ca. first 10 h). (E) Half-life of PER2::LUC and 
PER2::VENUS (mean ± SEM). (F) Western blot and band relative density measure for PER2::VENUS 
fibroblasts treated with either vehicle (Veh) or 25 μM MG132. MG132 significantly increased 
abundance of PER2::VENUS (nveh =3; nMG132 =3; Student’s T-test,  ** p <0.005). (G)  Mean 
PER2::VENUS fluorescence of individual SCN slices, treated with 50 μM MG132 (red) or vehicle 
(0.01% DMSO), at the peak of PER2::VENUS expression and tracked for 15 hours following 
treatment. (H) Fluorescence (mean ± SEM) at the peak (before treatment) and the trough (after 15 
hours treatment of MG132 and vehicle treated SCN slices).  A significant increase of fluorescence was 
observed in MG132 treated slices compared with vehicle treated (n =5, repeated-measures two-way 
ANOVA with Sidak’s multiple comparisons test, ** p <0.005).   (I) Half-life (mean ± SEM) of 
descending phase of the cycle (peak to trough) was significantly increased by Leptomycin B (LMB) 
treatment (nveh =5; nLMB =4, Student’s T-test, p <0.05). (J) Single cell analysis of PER2::VENUS 
fluorescence in representative SCN slices treated with either vehicle or 10 LMB (ng/μL). Mean 
fluorescence is shown by colored lines. (K) Representative trace showing autocorrelation analysis 
applied to a nuclear fluorescence trace measured for 80 h, to calculate circadian period. 
Autocorrelation peak locations are marked with arrows. (L) Mean ± SD of autocorrelation data (n = 
19). (M) Fluorescence intensity (mean ± SEM) measured in the nucleus (left panel) or cytoplasm 
(right panel) of individually tracked cells (n  =3) across 60 hours of recording.  
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Figure S4. Quantitative measures of PER2::VENUS intracellular dynamics. Related to Figures 3 and 4. 
(A)   Representative z-stack image of a dissociated (using trypsin) skin fibroblast. Cytoplasm is stained 
with CellTracker™ Red CMTPX and cell nucleus with Hoechst 33342, used to calculate cell volume. (B) 
Nuclear and cytoplasmic volume measurements (n =41 cells). (C) Autocorrelation curve for the peak 
of PER2::VENUS expression  (mean ± SD, n =27). (D) Quartile-quartile plot comparison between peak 
confocal concentrations and mean peak nuclear fluorescence, used as a calibration for converting 
fluorescence intensity into PER2::VENUS concentration. (E) Number of molecules in confocal volume. 
The confocal volume had previously been estimated at 0.59 ± 11 fL using Rhodamine 6G. The CK1ε
Tau allele had no effect on the numbers of PER2::VENUS molecules in the nucleus (nWT =28; nTau =31; 
T-test). (F) “Fast” component (as defined in Fig.3E) diffusion rate was not significantly different 
between WT and Tau mutant fibroblasts (nWT =19; nTau =25; T-test). (G) Proportion of cells displaying 
“fast” component is not significantly different between WT and Tau mutant fibroblasts (nWT =27; nTau 
=31 cells; T-test). All above group data are mean ± SEM. (H) Normalized fluorescence intensity (mean 
± SD) in bleached nuclear ROI (5μm diameter circle) for the recovery of photobleached WT (red, n = 
19) and CK1εTau (blue, n =25) temperature synchronized fibroblasts. (I) Fluorescence recovery curves 
(mean ± SD, blue line: n =14, red line: n =13) observed following nuclear ROI fluorescence bleaching 
(5μm diameter). (J) PF670462 treatment (1 uM) does not alter PER2::VENUS mobility within 
(intra-compartment) the cytoplasm or nucleus at CT2 (left) or CT12 (right), compared to WT (CT2: 
nWT,cyto =3; nPF,cyto =5; nWT,nuc =4; n,PF,nuc =6; CT12: nWT,cyto =4; nPF,cyto =5; nWT,nuc =5; n,PF,nuc =6; 
two-way ANOVA). (K) Intra-compartment (left) and inter-compartment (right) mobility of 
PER2::VENUS during PF670462 treatment. Note that same intra-compartment data are shown in 
separate graphs in (J) (blue bars). Intra-compartment mobility of PER2::VENUS does not change 
between CT, or compartment during treatment (nCT2,cyto =4; nCT12,cyto =5; nCT2,nuc =5; nCT12,nuc =6; 
two-way ANOVA). Inter-compartment mobility of PER2::VENUS does not change between CT, nor 
direction of movement Nucleus-to-cytoplasm or cytoplasm-to-nucleus) during treatment 
(nCT2,nuc->cyto =5; nCT12,nuc->cyto =13; nCT2,cyto->nuc =5; nCT12,cyto->nuc =12; two-way ANOVA).
 
 
 
Table S1. Percentage of neuropeptidergic cell type that express 
PER2::VENUS at different times of day. Related to Figure 1. 
(n = total number of brain sections, nbrains = 4)  
 
 VIP AVP GRP 
ZT n Mean SEM n Mean SEM n Mean SEM 
0 10 0 0 10 3.0 1.4 10 0 0 
12 7 99.2 0.46 10 99.3 0.58 8 7.1 3.5 
 
  
 
 
Supplemental experimental procedures 
 
Animals 
All animals were cared for in accordance with the UK Animals 
(Scientific Procedures) Act of 1986 with local ethical approval.  CK1εTau 
mice were used as previously described [S1].  Per1-luc reporter mice 
were acquired from Hitoshi Okamura (Kyoto University, Japan) [S2].  
Per1-/- mice were obtained from David Weaver (UMASS Medical 
School, Worcester, MA, USA) [S3]. 
 
Generation of PER2::VENUS animals 
A Venus-Neomycin construct (Figure S1) was assembled and sent to 
Biocenter Oulu (University of Oulu, Finland) for generation of knock-in 
mice using a gene-targeting strategy in 129Sv embryonic stem (ES) 
cells.  Resulting ES cells were injected into blastocyst stage C57Bl6 
embryos.  The F1 generation mice were tested for the presence of 
Per2Venus-Neo by Southern blot.  Neo was removed by crossing with a 
cre-recombinase deleter mouse line.  Mice from the F1 generation of 
this cross were genotyped for the presence of Per2Venus and the loss of 
Neo.  Positive mice were then crossed with C57/BL6 mice (>6 
generations) and subsequently bred to give homozygosity for the 
Per2Venus allele. 
 
Primers: 
P1: CTGTGTTTACTGCGAGAGT (Per2 exon 23) 
R1: GGGTCCATGTGATTAGAAAC (Per2WT) 
R2: TTGAAGAAGTCGTGCTGC (Per2Venus) 
 
Wheel-running 
 
 
Mice were entrained to a 12:12 light-dark (LD - 45-50 lux with white 
light and 5 lux in red light) cycle for at least 10 days prior to a 
schedule of continuous dim red light (DD) for 14 days.  Data were 
analyzed using ClockLab (ActiMetrix Inc., USA) running within Matlab 
(Mathworks, USA), as previously described [S4].  As well as circadian 
period, we calculated the daily activity patterns (from 3 days of DD 
activity data), which were then normalized, aligned and plotted as 
mean profiles for WT and Per2Venus genotypes. Non-Parametric 
circadian rhythm analysis (NPCRA) was applied to 12 days (“days” 
were adjusted to match the circadian period of the individual animal) 
of wheel-running data, which generated the following parameters: 
 
1. Relative Amplitude (RA) – Non-Parametric measure of 
rhythm amplitude between the mean lowest activity and mean 
highest daily activity measured over 5-hour and 10-hour time-
windows, respectively.  
RA = (Maxaverage – Lowaverage) / (Maxaverage + Lowaverage) 
 
2. Intra-daily Variability (IV) – Non-Parametric measure of 
frequency of activity/rest transitions. Can range between 0 
(data fits Sine wave) to 2 (Gaussian noise). 
 
3. Inter-daily Stability (IS) – how well daily activity patterns 
match on day-to-day basis. Can range from 0 (Gaussian noise) 
to 1 (high-stability). 
 
These collectively give an indication of circadian coherence and 
robustness. Robust, rhythmic behavior would be characterized as 
having a high RA, low IV and high IS. 
 
 
Fibroblast culture and temperature entrainment 
Primary cultured lung fibroblasts from PER2::VENUS mice were seeded 
in DMEM/10 % FBS/Penstrep and split in a 1:2 ratio until passage 6 
and then seeded into 3.5 cm dishes at a confluence ~ 300000 
cells/dish.  Once cells had attached, medium was changed and dishes 
transferred to an 5% CO2 incubator set to alternate with 12h cycles of 
high (37 °C) and low (32 °C) temperature for four cycles. The samples 
were then transferred to constant high temperature (37 °C). For 
imaging, cells were processed 4-6 h after transfer to 37 °C and for 
Western blots, cells were harvested every four hours for 48 h.  Dishes 
were washed in cold PBS before being frozen down at -80 ˚C and 
stored briefly before lysis and further processing.  Each dish was lysed 
in 50 µL cold lysis buffer: 1 % NP40/ 0.25% sodium deoxycholate/ 50 
mM Tris/ 1x Roche Protease Inhibitor Cocktail.  The lysates were 
sonicated on ice for 30 seconds and a soluble protein fraction was 
obtained by centrifuging for 10 min at 21000 g.  The protein lysates 
were normalized by BCA protein assay (Pierce, USA). 
 
Gel electrophoresis and Western blotting 
Protein lysates were subject to gel electrophoresis using NuPAGE 
Novex 4–12% Bis-Tris gradient gels (Life Technologies, USA), and run 
as per the manufacturer’s protocol, using the MOPS buffer system.  A 
wet tank system was used for protein transfer to PVDF membrane (30 
V for 1 h at 4 ˚C).  PVDF membranes were blocked for 1 hour (0.5% 
w/w non-fat dried milk (Marvel, USA) in TBST).  Membranes were then 
incubated with anti-rabbit GFP antiserum (1:10000, Abcam, U.K.) 
overnight at 4 °C, followed by three 20 min washes. The ECL Prime 
(GE Healthcare, USA) chemiluminescence detection system and 
imaged using the GelDoc system (Biorad, USA).  To check protein 
loading was even in the gels, duplicate gels were stained with 
 
 
Coomassie InstantBlue (Expedeon, uSA).  Densiometric quantification 
of Western blots was performed by Image Lab (Bio Rad, USA). 
 
Immunofluorescence 
PFA-fixed (4% PFA in phosphate buffer) SCN sections (40 µm) were 
blocked in 5% normal serum, matched to the primary antisera, in 
blocking buffer (BSA 1%, 0.3% Triton X-100 in PBS) for one hour, with 
gentle shaking.  Sections were incubated with primary antisera 
overnight, at 4 ˚C, with gentle shaking.  They were then washed twice 
for 5 minutes and incubated with secondary antiserum (Alexa 647, 
1:500, Life Technologies, USA) for one hour at room temperature.  
Sections were then washed twice for 5 minutes in wash buffer (BSA 
1%, 0.3% Triton X-100 in PBS) and then twice for 5 minutes in PBS. 
Sections were mounted with Vectashield with DAPI (Vectorlabs, USA), 
ready for confocal imaging.  Primary antisera used: rabbit anti-AVP 
(1:1000; Bachem, USA), guinea-pig anti-VIP (1:1000, Bachem, USA) 
and rabbit anti-GRP (1:1000; Immunostar, USA).  Both 
immunofluorescence and native VENUS florescence were imaged using 
a Zeiss 780 inverted confocal set-up (Zeiss, Germany).  Low 
magnification images were acquired using a 20x objective and high 
magnification images were acquired using a 63x oil objective.  
 
Fluorescence co-localization analysis 
Semi-automated cell counts were made using the “Nucleus Counter” 
ImageJ (NIH, USA) plugin [S5].  Mander’s co-localisation analysis was 
conducted using the Mander’s Coefficient plugin within ImageJ.  This 
analysis generates a table containing the Mander’s coefficient as well 
as values for M1 and M2, which distinguish the co-localisation of 
channel 1 with channel 2 and channel 2 with 1.  For example, all of 
 
 
channel 1 may co-localize with channel 2, but only 50% of channel 2 
may co-localize with channel1, in which case M1 =1.0, M2 =0.5. 
 
Organotypic slices 
SCN slice cultures were made as previously described [S6] and kept in 
culture for 3 days prior to real-time confocal imaging, or 7 days prior 
to bioluminescence recordings.  Whole-slice bioluminescence emissions 
were detected by photon multiplier tubes (Hamamatsu, Japan), set-up 
to count emitted photons every second in 6 minute bins. 
 
Real-time confocal microscopy 
Real-time imaging of fibroblasts and SCN slices was conducted using 
the Zeiss LSM780 inverted system (Zeiss, Germany), with a heated 
chamber kept at 37 °C.  Samples were placed in air-tight, glass-
bottom imaging dishes (Mattek, USA).  For long-term imaging, a 10x 
objective was used, and images acquired 2 frames per hour (fph), 30 
seconds scan time per frame, for ~70 hours.  Fibroblasts were imaged 
for ~ 70 hours at 6 fph, with a pixel dwell time of 1.58 µs. 
 
Drug treatments 
Temperature-entrained primary lung fibroblast at peak PER2::VENUS 
expression (~4 h after 37˚C→32˚C) were incubated for 6 h in either 
25 µM MG132 proteasome inhibitor (Cayman Chemical Company, USA) 
or vehicle.  Lysis etc. was performed as described as above.  Prior to 
all pharmacological treatments of Per2Venus SCN slices, “pre-treatment” 
fluorescence measures were acquired by confocal microscopy.  
Confocal image time-series were then acquired once drug treatments 
were applied to the slices, imaged at a rate of 4 frames per hour.  In 
SCN slices, cycloheximide (Sigma Aldrich, USA) was used at 40 µM, 
 
 
leptomycin B (Sigma Aldrich, USA) at 10 ng/mL and MG132 at 50 µM. 
Imaging data were either analyzed using mean fluorescence of the 
whole SCN or single cell fluorescence from the slice.  The latter 
employed the SARFIA package [S7] running within Igor Pro 
(Wavemetrics, USA) to select “cell-like” regions of interest.  
 
Fluorescence Correlation Spectroscopy and Quantified Time-lapse 
Imaging 
FCS and quantified time-lapse were conducted as previously described 
[S8], using a Zeiss LSM780 on an Axio observer Z1 microscope using a 
plan-apochromat 63x NA 1.4.  VENUS fluorescence was excited by 514 
nm laser light and emission collected between 518 and 535nm after 
passing through a pinhole set to one Airy unit.  Laser power was 
typically <5% total power, but was adjusted as necessary to avoid 
photo-bleaching and also to give a suitable count rate with a minimum 
1kHz counts per molecule.  The protocols as outlined in Kim et al. [S9] 
were followed with 10x10s runs used for each measurement.  Zen 
2010B software was used for data collection.  A custom made script 
for data fitting was written in MATLAB R2014b using the Optimisation 
Toolbox based on the Marquardt-Levenberg algorithm.  The 
distribution of FCS-measured peak concentration was also used to 
calibrate confocal data sets by quantile–quantile matching to a 
respective distribution of peak fluorescence as determined by image 
analysis. 
 
Fluorescence recovery After Photobleaching (FRAP) 
SCN slices were cut from their membrane insert on which they had 
been cultured, and positioned facedown on to the imaging glass to 
bring the tissue within the working distance of the 40x objective.  
 
 
FRAP was conducted with a Zeiss LSM780, using a 40x water 
immersion objective.  SCN slices used for FRAP experiments were 
either with or without casein kinase 1 inhibitor (PF670462) at 1 µM.  
FRAP measurements were taken at either CT2 or CT12.  Four different 
types of photobleach were used: whole nucleus, 3 µm diameter disc in 
the nucleus (part nucleus), whole cytoplasm, 3 µm diameter disc in 
the cytoplasm (part cytoplasm).  For each, the following protocol was 
used: 10 consecutive pre-bleach images acquired at low laser intensity 
(10%), followed by 100 times repeat exposure to photo-bleach at 
100% laser intensity, and post-bleach image acquisition at 10 frames 
per second. 
 
FRAP data analysis 
FRAP data were processed to remove background noise, corrected for 
acquisition bleaching and normalized to 100%.  The t1/2 of recovery 
was calculated and diffusion coefficient estimated using a simple 
diffusion model [S10] given by: D = 0.88w2 / 4 t1/2. 
These steps are outlined below: 
 
Mean fluorescence intensity was measured from the selected bleach 
area (Yraw), outside the cell (Ybg) and different unbleached cell (Y).   
 
1. Background subtraction: The raw data from the bleach spot was 
first background subtracted (Ybs) using the background 
measurement: 
 
Ybs = Yraw - Ybg 
 
 
 
2. Calculate acquisition bleaching correction factor: Ypc was fitted to 
a one-phase decay non-linear regression given by: 
 
Y = Y0(exp(-kt) 
 
where Y is Ypc, Y0 is Ypc at t = 0, k is the acquisition correction factor 
and t is time in seconds. 
 
3. Acquisition bleaching correction: The calculated value for k was 
used in the following equation and applied to background 
subtracted data: 
 
Ypc = Ybg + (Ybg,t=0 - (Ybg,t=0 (exp(-kt)))) 
 
Where Ypc is photo-bleach corrected signal, Ybg is background 
subtracted signal and Ybg,t=0 is background subtracted signal at t = 0 
 
4. Normalization: The value for Ypc is normalized so that Ypc at time 
= 0 is 100% 
 
5. Normalized data was fit to the standard FRAP equation: 
 
Y = A(1- exp(-k2t) 
 
where the value for k2 used calculate the t1/2 of fluorescence recovery: 
 
D = 0.88w2 / 4t1/2 
 
Circadian analyses of bioluminescence rhythms 
 
 
Bioluminescence rhythm data generated from PMTs were analyzed 
using non-linear fast-Fourier transform (NL-FFT) as part of circadian 
analysis software running within Biodare (Prof. A. Millar, University of 
Edinburgh; www.biodare.ed.ac.uk).  To avoid potential initialization 
artifacts in the analyses, the first 24 hours of the recordings were 
omitted.  Circadian period, amplitude relative phase and relative 
amplitude error (RAE) were calculated for each dataset. 
 
Statistical tests 
All graphs and statistics were generated using Prism (Graphpad, USA), 
unless specified.  Datasets containing two groups were tested by 
Student’s two-tailed t-test.  Data composed of three or more groups 
and a treatment variable were analyzed by two-way ANOVA with 
Tukey’s post-hoc multiple comparison test.  
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